Grifols reports Q3 adjusted EBITDA of EUR 482M, up 8.8% in constant currency

Revenues for the quarter totaled EUR 1,865B, increasing by 9.1% in constant currency year-over-year, driven by the Biopharma business. Nacho Abia, CEO of Grifols (GRFS), said: “Grifols maintains momentum as we deliver on our Value Creation Plan. We are delivering clear progress across our key priorities, underpinned by underlying demand and stable market dynamics. The company remains well-positioned to navigate market conditions and deliver sustainable long-term value for all stakeholders.”